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PURPOSE. Autosomal recessive retinitis pigmentosa (arRP) has re-
cently been associated with mutations in a novel gene, EYS,which is
a major gene for this disease. All published mutations so far are based
on conventional PCR and are not adequate to identify midsized DNA
rearrangements. This study was conducted to establish the preva-
lence of copy-number variations (CNVs) in the EYS gene in a cohort
of arRP patients, including individuals in whom only one pathogenic
change was detected by PCR-based sequencing.
METHODS. A multiple ligation–dependent probe amplification
(MLPA) was used for the molecular genetic analyses of CNVs by a
novel EYS-specific kit. PCR-based direct sequencing was used in
families where a pathogenic deletion or duplication was identified
in one allele. Bioinformatics analyses was undertaken to study the
effect of the mutations on protein structure and function.
RESULTS. Six novel pathogenic CNVs were identified. Also, the
presence of four midsized deletions was confirmed in patients
previously identified. Midsized genomic rearrangements in EYS
are disease causing in 4% of the families with no reported
mutations and constitute the second pathogenic variation in
15% of cases where a mutation has been detected by direct
sequencing.
CONCLUSIONS. This is the first report of a systematic CNV screen-
ing of EYS gene in a cohort of arRP patients. Results suggest
that midsized genomic rearrangements in EYS gene would be
a common event in the appearance of RP phenotype. An
efficient and cost-effective strategy validating a novel MLPA kit
as a complementary diagnostic method for EYS pathogenic
evaluation has been demonstrated. (Invest Ophthalmol Vis Sci.
2011;52:5625–5631) DOI:10.1167/iovs.11-7292
Retinitis pigmentosa (RP [MIM 268000]) is a generic name forinherited retinal dystrophies with loss of photoreceptor cells
and retinal pigment deposits at midperiphery of the retina, which
are visible on fundus examination. RP is characterized by primary
degeneration of the rod photoreceptors followed by secondary
degeneration of cones. This degeneration initially causes night
blindness, followed by constriction of the visual field, ab-
normal color vision, and progressive loss of visual acuity in
the later life.1 Prevalence of RP is approximately 1/4000
births with over 1 million individuals affected worldwide.2
This disease can be inherited as an autosomal dominant,
autosomal recessive, or an X-linked trait. All genes identified
to date are believed to account for roughly 50% of all retinal
dystrophy cases.3 The autosomal recessive form of RP is the
commonest worldwide, accounting for approximately 50%–
60% of cases.2 To date, a total of 32 genes have so far been
implicated in autosomal recessive RP (arRP; http://www.s-
ph.uth.tm.edu/Retnet/). However, all together these genes
appear to account for only 35%– 45% of total arRP cases.2
Recently we have identified a new gene, EYS, corresponding
to the RP25 locus,4 encoding an ortholog of Drosophila space-
maker (SPAM), as a commonly mutated gene in arRP.5 Spanning
over 2 Mb within the RP25 locus (6q12.1–6q15), EYS is the
largest eye-specific gene identified so far. The longest EYS isoform
encodes a protein of 3165 amino acids. Immunohistochemical
data reveal its localization in the outer segment of the photore-
ceptor layer. Although its role in visual function has not yet been
established, the evolutionary data, the new extensive bioinfor-
matic analyses, and the known function of the drosophila or-
tholog support a structural role for this new protein contributing
to the human retinal morphogenesis and architecture.6,7 The
initial identification of six independent mutations in our cohort of
Spanish families linked to RP25, together with the presence of
different mutations in arRP families from different origins, sup-
ports EYS as the first major gene for arRP.5,7–12
The identification of EYS causative mutation is important for
clinical diagnosis, predictions of the clinical course of the disease,
genetic counseling, and future gene-targeted therapies. Majority
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of mutations identified so far include missense, nonsense, mi-
crodeletions and insertions, and putative pathogenic changes in
the 5UTR region. However, no duplications and few midsized
deletions affecting EYS (to a few Kb) have been reported to date.
This low rate of identified copy-number variations (CNVs) leading
to arRP may be explained by the fact that the techniques usually
used, based on conventional PCR, are not adequate to identify
such rearrangements. Due to the technical difficulties in deter-
mining gene dosage in this size range, it is possible that the
proportion of mutations that are deletions or duplications has
been underreported, and the presence of midsized rearrange-
ments undetectable by PCR-based procedures would also explain
the failure to detect the second mutant allele in a significant
number of arRP families.7,9,10 In fact, only three studies have
investigated midsized insertions/deletions in EYS using compara-
tive genomic hybridization (CGH), CNVs analysis (Genechip 6.0
Affymetrix array; Affymetrix, Santa Clara, CA) and/or self-designed
multiple ligation probe-dependent amplification (MLPA) probes.5,7,9
Thus, the availability of a rapid accurate molecular diagnostic
complementary method to identify midsized rearrangements
could enhance acute clinical management as well as genetic
counseling. Here we report the pathogenic implication of EYS
CNVs in Spanish and French arRP populations using MLPA. For
this purpose we have tested and validated a novel EYS MLPA kit
(MRC-Holland, Amsterdam, the Netherlands) in 95 arRP patients,
including those where only one pathogenic change had previ-
ously been identified by PCR-based direct genomic sequencing.
We have identified novel EYS rearrangements in six arRP cases. In
addition, we have confirmed the presence of CNVs in four fami-
lies with midsized deletions previously detected by CGH and
self-designed MLPA.
MATERIALS AND METHODS
Subjects and Clinical Data
The study cohort comprises 95 Spanish and French unrelated pa-
tients affected by arRP, comprising 78 Spanish and 17 French
patients. A full ophthalmic examination was performed, and the
clinical diagnosis was based on visual acuity, fundus photography,
computerized testing of central and peripheral visual fields, and
electroretinography (ERG) findings. RP was defined as bilateral
visual loss, initial hemeralopy, restriction of visual field, gradual
increased bone spicule pigmentation and decrease of visual acuity,
attenuation of retinal vessels, reduced or undetectable electroreti-
nogram (ERG), and waxy disc pallor. The pattern of inheritance in
all participating patients was diagnosed based on the pedigree
TABLE 1. arRP Families with One Likely Pathogenic Change Included
in MLPA Studies in Order to Find a Second Mutant Allele
Family
ID
DNA Change
Previously
Reported by
Direct
Sequencing
Reference of
the Variation
DNA Change
Identified by MLPA
F51 p.Trp558X Audo et al.9 —
F228 p.Cys1001X Audo et al.9 c.(-340-?_748?del)
F444 p.Trp2783X Audo et al.9 —
F618 p.Cys183AlafsX74 Audo et al.9 c.(1300-?_1459?del)
F311 p.Pro2265GlnfsX46 Audo et al.9 —
F360 p.Ser1610PheFsX46 Audo et al.9 c.(6572-?_6725?del)
F109 p.Asp1682Tyr Audo et al.9 —
F393 p.Leu2189Pro Audo et al.9 —
F481 p.Gly2907Glu Audo et al.9 —
F116 p.Cys1176Arg Audo et al.9 —
F649 p.Cys2139Tyr Audo et al.9 —
F715 p.Asp1682Tyr Audo et al.9 —
F123 p.Asn745Ser Audo et al.9 —
F85 c.20231GC Audo et al.9 —
F221 p.Pro1739Leu Audo et al.9 —
RP60 p.Gln27ArgfsX16 Barraga´n et al.7 —
RP81 p.Asn745Ser Barraga´n et al.7 —
RP33 p.Trp1484X Barraga´n et al.7 —
RP383 p.Glu2503Lys Barraga´n et al.7 —
VRP8 p.Trp1484Arg Barraga´n et al.7 —
TABLE 2. List of Probes to Detect CNVs in the EYS Gene
EYS Exon
Ligation Site
NM_001142800.1
Distance to
Next Probe
(Kb)
Exon 1 6 nt after exon 1 66.8
Intron 1 415 nt before exon 2 144.1
Exon 2 — No probe
Exon 3 173 nt before exon 3 0.8
Exon 4 553–554 1.2
Intron 4 463 nt after exon 4 92.1
Exon 5 — No probe
Exon 6 — No probe
Intron 7 419 nt after exon 7 17.6
Exon 8 1806–1807 30.9
Exon 9 1935–1936 18.4
Exon 10 — No probe
Exon 11 2201–2202 39.2
Exon 12 2509–2510 0.2
Exon 12 177 nt after exon 13 238.1
Exon 13 2673–2674 60.0
Exon 14 2743–2742 reverse 51.8
Exon 15 2889–2890 33.2
Exon 16 3007–3008 9.9
Exon 17 233 nt before exon 17 0.3
Exon 17 3262–3263 15.7
Exon 18 — No probe
Exon 19 3503–3504 64.0
Exon 20 3632–3633 1.0
Exon 21 3743–3744 8.1
Exon 22 3810–3811 187.6
Exon 23 132 nt after exon 23 8.5
Exon 24 4146–4147 24.4
Exon 25 4415-intron 25 2.0
Exon 26 5328–5329 153.5
1.6Kb after exon 27 0.9
Intron 27 1.3Kb before exon 28
Intron 27 367 nt before exon 28 0.4
Exon 28 6398–6399 47.5
Exon 29 6540–6541 80.5
Exon 30 6710–6731 76.2
Exon 31 6798–6799 164.5
Exon 32 — No probe
Exon 33 28 nt after exon 33 67.2
Exon 34 1 nt after exon 34
reverse
14.5
Exon 35 7445–7444 reverse 120.3
Exon 36 7735–7736 58.0
Exon 37 8 nt after exon 37 17.1
Exon 38 12 nt after exon 38 0.9
Exon 39 8208–8209 10.1
Exon 40 8425–8426 15.4
Exon 41 8488–8489 35.8
Exon 42 143 nt before exon 42 5.2
Exon 43 8931–8932
Reference probe 18q21.1
Reference probe 9q21.31
Reference probe 4p16.3
Reference probe 2q36.1
Reference probe 17q11.1
Reference probe 19p13.2
Reference probe 22q12.3
Reference probe 6q23.3
The eight reference probes were used as controls.
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structure, characterized by more than one affected member and the
nonaffected progenitors in arRP families.
Globally, our cohort included 71 arRP patients with no known
mutation, 20 patients with a single mutation detected by PCR-based
direct sequencing, and four positive controls for CNVs. Also three
negative controls were included for technique normalization.
The Spanish cohort included five carriers of a pathogenic variant,
previously identified in a heterozygote state by PCR-based direct sequenc-
ing.7 (Table 1). Additionally, two midsized EYS deletion carriers previously
identified were included as positive controls.5 (Table 1).
The French cohort was composed of 15 patients with a previously
identified heterozygous EYS mutation,9 (Table 1) and included two
other homozygous individuals with midsized deletions as positive
controls for the validation of MLPA.
In addition, available samples of probands’ family members were
tested for cosegregation studies. An informed consent was obtained from
all participants for clinical and molecular genetic studies. The study con-
formed to the tenets of the Declaration of Helsinki.
MLPA Analysis
Gene dosage variation in EYS were analyzed by MLPA technology using
a novel MLPA kit especially designed for EYS. The P328-X1 EYS MLPA
Kit (MRC-Holland, Amsterdam, the Netherlands) contains 50 MLPA
probes designed to detect alterations in the copy number of one or
more exons in the EYS gene that can be implicated in arRP. In addition,
this kit also includes eight reference control probes that hybridize to
sequences in different regions of the genome (Table 2). The MLPA
FIGURE 1. MLPA profiles for control individuals (red) and for arRP patients with homozygous deletions (blue). The absence of the peak of EYS
was observed for exons 12, 13, 14, 15, 16, 17, 19, 33 and introns 12 and 17, indicated by arrows.
TABLE 3. Copy-Number Variations and Mutations Identified by PCR-Based Direct Sequencing of EYS Gene in Spanish and French Families
Family ID Exon DNA Change Protein Change Type of Change Reference for the Variation
F228 3–4 Deletion c.(340-?_748?del)* Heterozygous This study
20 c.3003TA p.Cys1001X Heterozygous Audo et al.9
RP1 3–4 Duplication c.(340-?_748?dup)* Heterozygous This study
43 c.8897GA pGly2945Glu Heterozygous This study
F618 4 c.547delT p.Cys183AlafsX74 Heterozygous Audo et al.9
9 Deletion c.(1300-?_1459?del)† Heterozygous This study
RP73 12 Deletion c.(1767-?_2023?del) p.Cys590TyrfsX4 Heterozygous Abd-El Aziz et al.5/This study
28 c.5857GT p.Glu1953X Heterozygous Abd-El Aziz et al.5
F735 12 Deletion c.(1767-?_2023?del) p.Cys590TyrfsX4 Homozygous Audo et al.9/This study
RP3 13–14 Deletion c.(2024-?_2259?del) p.Gly676GlufsX9del Homozygous This study
RP5 15–19 Deletion c.(2260-?_2992?del) p.Ser754AlafsX6 Homozygous Abd-El Aziz et al.5/This study
RP2 16–19 Deletion c.(2382-?_2992?del) p.Cys795HisfsX4 Heterozygous This study
F360 26 c.4827_4830delTTCA p.Ser1610PhefsX7 Heterozygous Audo et al.9
33 Deletion c.(6572-?_6725?del)‡ Heterozygous This study
F115 32–33 Deletion p.Asp2142AlafsX14 Homozygous Audo et al.9/This study
c.(6425-?_6725?del)
* There are no probes to detect possible deletions/duplications in exons 5 and 6.
† There are no probes to detect possible deletions in exon 10.
‡ There are no probes to detect possible deletions in exon 32.
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reaction was performed in a thermal cycler (Biometra TGRADIENT;
Biometra, Goettingen, Germany), following the manufacturer’s recom-
mendations (http://www.mlpa.com).
Capillary electrophoresis analysis was performed in an analyzer (3730
DNA analyzer; Applied Biosystems, Foster City, CA), and commercially
available software (GeneMarker v. 1.75; Softgenetics, State College, PA)
was used for data analysis. We normalized the samples comparing the
peak heights of patients versus controls. In addition, we included positive
controls harboring three homozygous arRP EYS deletion patients (F115,
F735, and RP5) and one patient with a heterozygous deletion (RP73).5,9
The MLPA analysis criteria were as follows: (1) normal if the individual
dosage quotient values are within 0.8–1.0; (2) deletions or duplications if
the dosage quotient values are around 0.5 or 1.5, respectively; and (3) the
mean SD of all samples for each peak should be below 10%.
PCR-Based Direct Genomic Sequencing of EYS
To find the second pathogenic variation in those families where a new
deletion/duplication was identified in one of the alleles by MLPA, we
sequenced EYS by PCR-based direct sequencing. Moreover, these results
helped to discard the presence of allelic variants in the probe target
sequences that may have led to false positive results. PCR and sequencing
procedures follows the protocols previously described in Barra´gan et al.7.
To evaluate the pathogenicity of the novel variants, software (Net-
phos2.1; NetPhos2.0 Server, http://www.cbs.dtu.dk/services/NetPhos/)
was used to predict the alteration in phosphorylation.13
All the changes were assigned a nucleotide number starting at the first
translation base of EYS isoform according to the GenBank Reference
Sequence Version FJ416331; GI: 212675237; Transcript Reference Se-
quence: NM_001142800.1 (ensemble entry ENST00000503581).
RESULTS
Validation of EYS P328-X1 MLPA Kit
Using a novel MLPA P328-X1 Kit, we first confirmed the
presence of four midsized deletions in patients previously
identified by CGH and self-designed MLPA.5,9 They consisted
of three midsized homozygous deletions and one patient
with a heterozygous deletion affecting exons 15–19, 32–33,
and 12, in control families RP5, F115, F735, and RP73,
respectively (Fig. 1, Table 3).
Identification of Novel Very Likely
Pathogenic CNVs
MLPA analyses led to the identification of six novel EYS rear-
rangements. The sequence variants were designated in accor-
dance with the Human Genome Variation Society recommen-
dations (http://www.hgvs.org/mutnomen/) (Table 1).
In the RP1 family, we found a heterozygous duplication of
exons 3 and 4 in the affected individual (Fig. 2). It is the first
FIGURE 2. MLPA profiles for control individuals (red) and for arRP patients with heterozygous deletions (blue). For the RP patients a decrease of
dosage was observed for EYS exons 3, 4, 12, 16, 17, 19, 33 and introns 4, 12, and 17, indicating a heterozygous deletion. In the case of RP1 family,
an increment for the dosage of EYS exons 3 and 4 indicates a heterozygous duplication for these exons.
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time a duplication in EYS is reported.
Direct sequencing of this patient’s DNA revealed a
c.8897GA (p.Gly2945Glu) as the second pathogenic change
(Fig. 3). The amino acid substitution locates in an EGF domain
of SPAM. Turning to evolutionary conservation, this glycine is
present in this position in EYS homologues previously reported
by our group.7 The substitution of glycine to glutamate in
position 2945 introduces an acidic polarity in a previously
hydrophobic position. In addition, this change is not tolerated
according to computational predictions, since it implies the
loss of one phosphorylation site (NetPhos2.1).
In the RP3 family index patient, we found a novel homozy-
gous deletion including exons 12 and 13. The segregation
analysis in the family was consistent with the recessive pattern
of inheritance (Table 4).
Index patients in F225, F618, and F360 families had been
previously described as carrying truncating mutations identi-
fied by PCR-based direct sequencing (Table 1). After MLPA
screening, we have identified three midsized heterozygous
deletions, affecting exons 3–4, 9, and 33, respectively, as the
second pathogenic change in the EYS gene. In addition, family
segregation in available members (F618 and F360), supported
the pathogenic nature of those mutations (Table 4).
The screening of the index patient from family RP2 re-
vealed a heterozygous deletion involving exons 16–19. How-
ever, in this case, PCR-based direct sequencing failed to iden-
tify the second mutant allele.
DISCUSSION
Molecular diagnosis of RP is a challenging task given the im-
portant genetic heterogeneity of these groups of diseases. EYS
represents a major arRP gene, as can be appreciated in view of
the high number of EYS mutations detected by PCR-based
direct genomic sequencing reported in different arRP patients
and the diverse ethnic origins of these families.5,7–12 However,
mutations due to midsized deletions (a few kilobases) in EYS
have seldom been reported.
Typical screening protocols using conventional PCR-based
sequencing methods are only able to detect small duplications/
deletions (a few base pairs) and are dependent on the size of
the amplified fragment in one reaction (1 Kb maximum) On
the other hand, cytogenetic techniques can exclusively detect
large alterations ranging several megabases in size. None of the
FIGURE 3. (A) Electropherogram of EYS mutation at nucleotide posi-
tion c.8897GA in the proband of family RP1. (B) Alignment of the
SPAM peptide sequence in human and in other species using CLUSTAL
W (1.82) multiple sequence alignment.
TABLE 4. Segregation of Pathogenic EYS Mutations in arRP Patients and Family Members
Index Patient,
Family Members Family Exon Nucleotide Exchange Protein effect Allele State Reference
CIC01001 F618 4 c.547delT p.Cys183AlafsX74 Het Audo et al.9
9 Deletion c.(1300-?_1459?del)** Het This study
Unaff. spouse 4 — — — Audo et al.9
CIC03487 9 — — — This study
Aff. sister 4 c.547delT p.Cys183AlafsX74 Het Audo et al.9
CIC03499 9 Deletion c.(1300-?_1459?del)** Het This study
Unaff. mother 4 c.547delT p.Cys183AlafsX74 Het Audo et al.9
CIC03605 9 — — — This study
03/2522b RP3 13–14 Deletion p.Gly676GlufsX9del Hom This study
Unaff. daughter 13–14 Deletion p.Gly676GlufsX9del Het This study
03/2523b
Unaff. son 13–14 Deletion p.Gly676GlufsX9del Het This study
03/2524b
Unaff. niece 12227 13–14 Deletion p.Gly676GlufsX9del Het This study
Unaff. nephew 13–14 Deletion p.Gly676GlufsX9del Het This study
12226
F360 26 c.4827_4830delTTCA p.Ser1610PhefsX7 Het Audo et al.9
CIC00529 33 Deletion c.(6572-?_6725?del)*** Het This study
Unaff. father 26 c.4827_4830delTTCA p.Ser1610PhefsX7 Het Audo et al.9
CIC00794 33 — — — This study
Unaff. mother 26 — — — Audo et al.9
CIC00528 33 Deletion c.(6572-?_6725?del)*** Het This study
Unaff. sister 26 — — — Audo et al.9
CIC00710 33 Deletion c.(6572-?_6725?del)*** Het This study
Unaff. sister 26 c.4827_4830delTTCA p.Ser1610PhefsX7 Het Audo et al.9
CIC00766 33 — — — This study
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two approaches are powerful enough and adequate to detect
CNVs affecting specific regions corresponding to a few kilo-
bases. There are some traditional techniques used to detect
midsized deletions/duplications such as southern blot or quan-
titative/semiquantitative PCR, but they are expensive, time
consuming, and not suitable for high-throughput results. For
example, only a few samples can be run per gel by southern
blot, and tests may take several days; using real-time PCR, the
number or targets that can be interrogated in a reaction is
limited by the number of fluorophores available. Also, the cost
of buying fluorescently labeled probes for every intended tar-
get can be prohibitive.
For these reasons we sought to perform CNV screening using
MLPA technology (see Supplementary Material and Supplemen-
tary Fig. S1, http://www.iovs.org/lookup/suppl/doi:10.1167/
iovs.11-7292/-/DCSupplemental) in arRP patients, including the
ones where only one pathogenic change had been identified by
PCR-based direct sequencing.
The major advantages of MLPA are ease of use, high
throughput, and being cheaper than other techniques such as
real-time PCR or CGH. The MLPA method allows the detection
of midsized insertions/deletions ranging from the probe size
(40 bases) to a few Kb (depending on the length of tested
gene) in a large number of individuals within a short time
period. This technique is being used extensively in the molec-
ular diagnosis of a wide range of diseases caused by deletions
or duplications of one or more exons in specific genes.14,15 In
this case the novel MLPA kit has a maximum detection range of
2 Mb, corresponding to the EYS genomic interval.
First, to evaluate the novel MLPA kit, we confirmed the
presence of four midsized deletions in patients previously
identified by CGH and self-designed MLPA.5,9 Therefore, vali-
dation of the novel kit used was successfully achieved.
As a result of the MLPA screening for CNVs, we have identified
six novel EYS rearrangements in six out of 91 unrelated patients
with arRP (see Supplementary Fig. S2, http://www.iovs.org/lookup/
suppl/doi:10.1167/iovs.11-7292/-/DCSupplemental). Majority of
identified CNVs are predicted to generate a frameshift leading to
a premature stop codon, and probably, most of these altered
mRNA transcripts will be degraded through nonsense mediated
decay.16 In the case of F228, RP1, and F360 families, we cannot
predict the putative protein effect of the mutation, since the extent
of the CNVs is unknown, due to the absence of probes for the
adjacent exons (see Supplementary Fig. S3, http://www.iovs.org/
lookup/suppl/doi:10.1167/iovs.11-7292/-/DCSupplemental). It is
very likely that they would lead to a frame shift generating a novel
stop codon, or the loss/gain of a significant portion of the protein,
rich in important functional domains. In both cases the outcome
would be sufficient to be pathogenic.
The identification of different CNVs in EYS in three out of
71 families with no known mutations, reveals a probable mu-
tation frequency of 4% of the cases, indicating that this kind
of genomic rearrangements in EYS gene would be a significant
possibility in the appearance of the RP phenotype. Also, three
out of 20 families carrying a mutation in one allele detected by
PCR-based direct sequencing were found to have a rearrange-
ment in the second mutated allele in EYS. This indicates that,
at least, 15% of families with one heterozygous change identi-
fied by PCR-based direct sequencing would be a carrier of a
midsized pathogenic deletion/insertion. However, it is still
possible that some of the 17 remaining cases with only one
pathogenic mutation also carry deletions/duplications affecting
the EYS gene, as the current P328-X1 probemix does not
contain probes for exons 2, 5, 6, 10, 18, and 32. Therefore, the
P328-X1 probemix must be updated to improve both the ac-
curacy and detection rate of rearrangements in EYS by MLPA.
In summary, this is the first report of a systematic CNV
screening of EYS gene in a large cohort of arRP patients. Our
results show that midsized genomic rearrangements in EYS are
a common event in the development of the RP phenotype.
They are responsible for the disease in about 4% (3/71) of the
families with no reported mutations and constitute the second
pathogenic variation in approximately 15% (3/20) of cases
where a mutation has been detected by PCR-based direct
sequencing. Globally, 5% (5/91) of all arRP families included
in this study bear a pair of EYS mutations as the likely cause of
the disease, and 1% (1/91) present a heterozygous mutation.
Of the mutations, 7% (6/91) are midsized rearrangements,
whereas 2% (2/91) are single-nucleotide substitutions, and
2% (2/91) are other variants detectable by PCR-based se-
quencing (Fig. 4).
FIGURE 4. Distribution of EYS mutations along the domain structure of SPAM. Large rearrangements are indicated in red. Blue is used for depicting
small deletions and single nucleotide changes. Mutations previously identified by PCR-based direct sequencing are indicated by an asterisk.
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Determination of the underlying genetic defects in a patient
is a prerequisite for gene or mutation-specific therapy; thus,
this knowledge is crucial for future therapies design. There-
fore, the development of efficient and cost-effective strategies
to detect mutation is mandatory. We have demonstrated that
MLPA is an efficient and cost-effective strategy as a comple-
mentary diagnostic method for EYS pathogenic evaluation in
arRP families.
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